Nicotinamide mononucleotide has been studied in 793 papers since 1987: 33 trials and 16 observational studies in people, 414 in animals, 164 in cells, 147 reviews; 178 in the past year. Its furthest trials in people are at phase 2. The newest story, Nov 6, 2026: “Lactate-linked protein change limits death in cultured ovarian cells”.
Nicotinamide mononucleotide extends lifespan in G608G HGPS mice; independent labs reproduce higher mouse NAD+ and lower inflammation, although inflammation results disagree. Human trials report increased blood NAD+, while a trial shows no clear brain NAD+ effect. Some human papers declare developer ties; seven trials concern aging, and two trials ended over a year ago without posted results or citing papers.
1,453 findings in 531 papers from 2011 to 2026, 62 of them since April 2026
Independent labs found the same change in cells, mice and people. 207 independent labs in 33 countries; 11 trials, 8 about aging, 2 with no results posted.
“Compared with the placebo, NMN supplementation was associated with a statistically significant but modest reduction in resting DBP (WMD, -2.15 mmHg; 95% CI: -3.68 to -0.61).”
Cells, mice and humans: replicated by independent labs. Worms or flies: a single group.
C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.
Labs are independent when their papers share no last author and no institution.
Against: findings that point the other way from most findings on the same outcome.
About aging: the drug’s trials about aging. The total counts its trials for every use.
No results posted: trials that ended over a year ago with no results on ClinicalTrials.gov and no paper reporting them.
Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.
207 independent labs in 33 countries
35 findings against
11 trials, 8 about aging, 2 with no results posted
Funders: National Natural Science Foundation of China and others
What did studies of nicotinamide mononucleotide find?
527
Studies of nicotinamide mononucleotide measured 527 outcomes; the most studied are NAD+ (42 studies), apoptosis (23) and oxidative stress and ROS signaling (20).
Nicotinamide mononucleotide showed no clear effect on NAD+ in humans.
“Like NR, NMN supplementation did not lead to a significant detectable change in brain NAD levels over time, nor at the end of supplementation on day 8 (LME, p = 5.57x10−2), or on day 9 (LME, p = 0.24), when blood NAD levels were at their peak ( G).”
“Administering exogenous NAD+ precursors, such as Nicotinamide Mononucleotide (NMN) or Nicotinamide Riboside (NR), successfully restores the NAD+ pool”
↓downin mice8↓downin human cells5↓downin mouse cells4↓downin pigs2+4
23 studies
Nicotinamide mononucleotide inhibits apoptosis in human cells (testosterone-treated cells).
“NMN promoted SIRT2-mediated deacetylation of LDHA at K119, which enhanced glycolytic activity, promoted proliferation, and inhibited apoptosis in ovarian GCs.”
Nicotinamide mononucleotide decreases oxidative stress and ROS signaling in mice (APP/PS1 transgenic Alzheimer's disease model).
“NMN supplementation also enhanced ATP production, mitochondrial function, and synaptic density in the hippocampus while reducing oxidative stress and Aβ accumulation in the brain.”
Nicotinamide mononucleotide decreases oxidative stress and ROS signaling in mice (chronic and binge ethanol feeding).
“NMN significantly counteracted the ethanol-induced elevation in liver MDA levels and restored the diminished glutathione (GSH) and superoxide dismutase (SOD) activity levels caused by ethanol exposure.”
Animalschronic and binge ethanol feedinglivern = 10
Nicotinamide mononucleotide decreases cellular senescence in mice (high-fat diet-fed aging mice) (P < 0.01 for P21 and β-gal; P < 0.05 for SASP markers).
“decreased the expression concentrations of senescence-associated secretory phenotype markers (Serpine1, MMP3, CXCL-1, CXCL-10, and P16; P < 0.05), senescence markers (P21 and β-galactosidase (β-gal); P < 0.01)”
Animalshigh-fat diet-fed aging miceheart400 mg/kg in drinking water7 momales
Nicotinamide mononucleotide decreases inflammation in mice (acute kidney injury).
“NMN-PEG was found to augment peroxisomal function in PTCs via ACAA1, leading to increased β-oxidation of LCFAs and VLCFAs to mitigate ferroptosis and inflammation.”
Nicotinamide mononucleotide inhibits inflammation in human cells (TNF-α-induced inflammatory model).
“Multi-laboratory verification using the novel cosmetic ingredient β-nicotinamide mononucleotide (NMN) confirmed both the anti-inflammatory activity of NMN and the high reproducibility of the assay.”
↓downin mouse cells5↓downin mice4↓downin human cells2↓downin cells1+3
15 studies
Nicotinamide mononucleotide decreases reactive oxygen species in mouse cells (oxygen-glucose deprivation/reoxygenation).
“OGD/R exposure induced severe mitochondrial structural damage, intracellular depletion of NAD+ and ATP, and excessive reactive oxygen species (ROS) generation; these pathological phenotypes were partially attenuated by NMN supplementation.”
Nicotinamide mononucleotide decreases reactive oxygen species in oocytes after prolonged maturation.
“Notably, supplementation with 100 μM NMN reversed these negative effects, significantly increasing the total number of blastocyst cells, reducing ROS levels”
↓downin cells2↓downin mice2↓downin human cells1↓downin mouse cells1+1
7 studies
Nicotinamide mononucleotide decreases ferroptosis in mice (acute kidney injury).
“NMN-PEG was found to augment peroxisomal function in PTCs via ACAA1, leading to increased β-oxidation of LCFAs and VLCFAs to mitigate ferroptosis and inflammation.”
FASEB journal : official publication of the Federation of American Societies for Experimental Biology·
Nicotinamide mononucleotide improves mitochondrial function in PCOS oocytes.
“NMN helps reverse the decline in PCOS oocyte quality by mitigating oxidative stress, improving mitochondrial function, and preserving spindle morphology”
Nicotinamide mononucleotide decreases diastolic blood pressure in humans (compared with placebo) (WMD -2.15 mmHg).
“Compared with the placebo, NMN supplementation was associated with a statistically significant but modest reduction in resting DBP (WMD, -2.15 mmHg; 95% CI: -3.68 to -0.61).”
Nicotinamide mononucleotide increases blood NAD+ concentration in humans (hospitalized patients with COVID-19 and AKI) (16.0 ± 6.9 μg/mL at baseline to 42.6 ± 25.6 μg/mL at day 14).
“MIB-626 treatment significantly but gradually raised blood NAD+ levels to a peak between 5 to 14 days”
Human trialhospitalized patients with COVID-19 and AKIMIB-626 tablets1.0 g twice daily14 days
Nicotinamide mononucleotide decreases systolic blood pressure in humans (subgroup analysis of adults aged 60 years and older) (WMD -3.94 mmHg).
“NMN supplementation resulted in a significant reduction in SBP specifically among participants aged 60 years and older (WMD: -3.94 mmHg; 95% CI: -7.06 to -0.82).”
Human trialsubgroup analysis of adults aged 60 years and older
Studies link nicotinamide mononucleotide with 14 measures, among them LPS-altered metabolomic features, lipid-droplet-associated marker transcripts and inflammation.
LPS-altered metabolomic features
↕mixedin human cells1
1 study
Nicotinamide mononucleotide is associated with LPS-altered metabolomic features in human cells (Pg LPS-stimulated cells) (30 features changed in the opposite direction to LPS-induced changes).
“Following false discovery rate correction, 30 features altered by LPS showed significant changes in the opposite direction following NMN co-treatment.”
Nicotinamide mononucleotide is associated with mitochondrial DNA copy number in mice (increased in small mitochondria and decreased in large mitochondria).
“increasing mitochondrial DNA copy number above both young and aged levels in small mitochondria while further reducing it below aged levels in large mitochondria.”
Animalsincreased in small mitochondria and decreased in large mitochondriacumulus granulosa cell
A preprint reports longer lifespan in female mice; independent labs report reduced oxidative stress but opposing inflammation changes in mice. Human trials report increased blood NAD+; six trials concern aging, and two across all uses ended over a year ago without posted results. The National Natural Science Foundation of China supports 322 findings; company employees coauthor papers, and companies sponsor most trials.
A preprint reports longer female mouse lifespan with nicotinamide mononucleotide; independent labs report mouse NAD+ increases and opposing inflammation changes, while human trials raise blood NAD+. Six registered trials concern aging; four trials ended over a year ago without posted results or linked papers. Papers name National Natural Science Foundation of China funding and developer ties; companies sponsor six trials.
Summary rewritten as its findings changed.
As it read before
A mouse preprint reports longer female lifespan with nicotinamide mononucleotide; independent labs report reduced senescence in human cells and improved human sleep quality. Human trials raise blood NAD+; insulin-resistance results differ. Six trials concern aging; across all uses, four ended over a year ago without posted results or linked papers, and most are sponsored by MetroBiotech, Abinopharm and Shanghai Cell Therapy Group.
Summary rewritten as its findings changed.
As it read before
NMN extends lifespan in HGPS-model mice; independent labs reproduce mouse NAD+ increases and oxidative-stress reductions, but inflammation results conflict. Human results here come from one group; two registered trials concern aging, two trials ended over a year ago without posted results, and authors have company affiliations and companies sponsor trials.
Summary rewritten as its findings changed.
As it read before
Independent labs reproduce increased SIRT3 in mice; inflammation usually decreases but increases in a male-mouse preprint. Human work comes from one group. Two trials ended over a year ago without posted results or citing papers; Abinopharm and Shanghai Cell Therapy Group sponsor two of five trials, and the National Natural Science Foundation of China supports 10 findings.
A lactate-based protein modification supported transport channels and reduced cell death in experiments with lab-grown granulosa cells, which support developing eggs.A lactate-based protein modification supported transport channels and reduced cell death in experiments with lab-grown granulosa cells, which support developing eggs.
In goat egg-cell experiments, a supplement restored a metabolic molecule, improved measures of cell function and improved early embryo development.In goat egg-cell experiments, a supplement restored a metabolic molecule, improved measures of cell function and improved early embryo development.
Sorting individual mitochondria in mouse egg cells revealed age-related DNA differences that pooled measurements missed, with supplementation producing different effects…Sorting individual mitochondria in mouse egg cells revealed age-related DNA differences that pooled measurements missed, with supplementation producing different effects across groups.
Female mice given 5% nicotinamide mononucleotide cream after ultraviolet B exposure three times weekly through week 25 showed no protection against skin damage.Female mice given 5% nicotinamide mononucleotide cream after ultraviolet B exposure three times weekly through week 25 showed no protection against skin damage.